|Bid||0.00 x 4000|
|Ask||0.00 x 4000|
|Day's range||8.23 - 8.66|
|52-week range||0.25 - 18.77|
|Beta (5Y monthly)||4.30|
|PE ratio (TTM)||N/A|
|Earnings date||04 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.88|
In the coronavirus vaccine market, several players -- including Moderna and Pfizer -- are currently benefiting from a first-mover advantage. One of them is Ocugen (NASDAQ: OCGN), a company that partnered with India-based Bharat Biotech to develop and market a COVID-19 vaccine called Covaxin. Like many other meme stocks, shares of Ocugen have been highly volatile since the beginning of the year -- and a recent regulatory breakthrough in India sent the company's stock soaring through the roof.
These COVID-19 vaccine developers are all moving in response to strong late-stage results for Valneva's VLA2001.
Ocugen (NASDAQ: OCGN) shares took center stage earlier this year when the biotech joined the coronavirus vaccine race. The company partnered with India's Bharat Biotech to co-develop and co-commercialize Bharat's vaccine candidate -- Covaxin -- in the U.S. As a result, Ocugen shares soared as much as 763% in about six weeks. Now, some investors might be wondering if Ocugen will hang onto this positive momentum -- or whether the stock is heading for a crash.